Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study GroupMichael Lübbert, Stefan Suciu, Liliana Baila, et al.
Annals of Hematology|November 25, 2015
Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study GroupMichael Lübbert, Stefan Suciu, Anne Hagemeijer, et al.
Blood|November 29, 2002
Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 studyChristine M Segeren, Pieter Sonneveld, Bronno van der Holt, et al.
Blood|November 8, 2008
Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparisonJan J Cornelissen, Bronno van der Holt, Gregor E G Verhoef, et al.
Haematologica|December 18, 2009
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemiaWendy Deenik, Jeroen J W M Janssen, Bronno van der Holt, et al.
Blood|May 8, 2024
Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trialFabio Efficace, Michal Kicinski, Corneel Coens, et al.
Blood|January 4, 2008
Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemiaWendy Deenik, Bronno van der Holt, Gregor E G Verhoef, et al.
Haematologica|September 24, 2016
Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromesEline M P Cremers, Theresia M Westers, Canan Alhan, et al.
JCO Precision Oncology|February 17, 2022
Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete RemissionJurjen Versluis, Burak Kalin, Wendelien Zeijlemaker, et al.
British Journal of Haematology|October 11, 2011
Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programmeLieke H van der Helm, Canan Alhan, Pierre W Wijermans, et al.
Pageof 5